These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 17495881

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
    François H, Coppo P, Hayman JP, Fouqueray B, Mougenot B, Ronco P.
    Am J Kidney Dis; 2008 Feb; 51(2):298-301. PubMed ID: 18215707
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. BNP as a marker of the heart failure in the treatment of imatinib mesylate.
    Park YH, Park HJ, Kim BS, Ha E, Jung KH, Yoon SH, Yim SV, Chung JH.
    Cancer Lett; 2006 Nov 08; 243(1):16-22. PubMed ID: 16388897
    [Abstract] [Full Text] [Related]

  • 26. Clinical pharmacokinetics of imatinib mesylate.
    Levêque D, Maloisel F.
    In Vivo; 2005 Nov 08; 19(1):77-84. PubMed ID: 15796158
    [Abstract] [Full Text] [Related]

  • 27. No influence of 3435C>T ABCB1 (MDR1) gene polymorphism on risk of adult acute myeloid leukemia and P-glycoprotein expression in blast cells.
    Jamroziak K, Balcerczak E, Cebula B, Janus A, Mirowski M, Robak T.
    Ther Drug Monit; 2006 Oct 08; 28(5):707-11. PubMed ID: 17038891
    [Abstract] [Full Text] [Related]

  • 28. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
    van der Holt B, Van den Heuvel-Eibrink MM, Van Schaik RH, van der Heiden IP, Wiemer EA, Vossebeld PJ, Löwenberg B, Sonneveld P.
    Clin Pharmacol Ther; 2006 Nov 08; 80(5):427-39. PubMed ID: 17112800
    [Abstract] [Full Text] [Related]

  • 29. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome.
    Beumer JH, Natale JJ, Lagattuta TF, Raptis A, Egorin MJ.
    Pharmacotherapy; 2006 Jul 08; 26(7):903-7. PubMed ID: 16803422
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
    Bolton AE, Peng B, Hubert M, Krebs-Brown A, Capdeville R, Keller U, Seiberling M.
    Cancer Chemother Pharmacol; 2004 Feb 08; 53(2):102-6. PubMed ID: 14605865
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Impact of ABCB1 (MDR1) haplotypes on tacrolimus dosing in adult lung transplant patients who are CYP3A5 *3/*3 non-expressors.
    Wang J, Zeevi A, McCurry K, Schuetz E, Zheng H, Iacono A, McDade K, Zaldonis D, Webber S, Watanabe RM, Burckart GJ.
    Transpl Immunol; 2006 Jan 08; 15(3):235-40. PubMed ID: 16431292
    [Abstract] [Full Text] [Related]

  • 34. A Canadian paediatric brain tumour consortium (CPBTC) phase II molecularly targeted study of imatinib in recurrent and refractory paediatric central nervous system tumours.
    Baruchel S, Sharp JR, Bartels U, Hukin J, Odame I, Portwine C, Strother D, Fryer C, Halton J, Egorin MJ, Reis RM, Martinho O, Stempak D, Hawkins C, Gammon J, Bouffet E.
    Eur J Cancer; 2009 Sep 08; 45(13):2352-9. PubMed ID: 19505817
    [Abstract] [Full Text] [Related]

  • 35. Drug transporters and imatinib treatment: implications for clinical practice.
    Eechoute K, Sparreboom A, Burger H, Franke RM, Schiavon G, Verweij J, Loos WJ, Wiemer EA, Mathijssen RH.
    Clin Cancer Res; 2011 Feb 01; 17(3):406-15. PubMed ID: 21163869
    [Abstract] [Full Text] [Related]

  • 36. Monitoring of plasma imatinib concentration for the effective treatment of CML patients.
    Tsutsumi Y, Kanamori H, Yamato H, Ehira N, Miura T, Kawamura T, Obara S, Tanaka J, Asaka M, Imamura M, Masauzi N.
    Leuk Res; 2004 Oct 01; 28(10):1117-8. PubMed ID: 15289027
    [No Abstract] [Full Text] [Related]

  • 37. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib.
    Franceschino A, Tornaghi L, Benemacher V, Assouline S, Gambacorti-Passerini C.
    Haematologica; 2008 Feb 01; 93(2):317-8. PubMed ID: 18245661
    [Abstract] [Full Text] [Related]

  • 38. [Pharmacokinetic-pharmacodynamics relationships of imatinib (Glivec)].
    Delbaldo C.
    Therapie; 2007 Feb 01; 62(2):87-90. PubMed ID: 17582306
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment.
    Crettol S, Déglon JJ, Besson J, Croquette-Krokar M, Hämmig R, Gothuey I, Monnat M, Eap CB.
    Clin Pharmacol Ther; 2006 Dec 01; 80(6):668-81. PubMed ID: 17178267
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.